| Literature DB >> 15242253 |
Constantine S Mitsiades1, Nicholas Mitsiades.
Abstract
Celgene, in collaboration with the National Cancer Institute, is developing CC-5013, the lead compound in a series of thalidomide derivatives that inhibit TNFalpha overproduction, for the potential treatment of hematological and solid tumor cancers and inflammatory diseases.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15242253
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472